PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
0.79%
Positive revenue growth while WEED.TO is negative. John Neff might see a notable competitive edge here.
66.19%
Gross profit growth under 50% of WEED.TO's 177.94%. Michael Burry would be concerned about a severe competitive disadvantage.
131.77%
EBIT growth above 1.5x WEED.TO's 19.51%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
131.77%
Operating income growth above 1.5x WEED.TO's 19.51%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
94.53%
Net income growth at 50-75% of WEED.TO's 156.06%. Martin Whitman would question fundamental disadvantages in expenses or demand.
94.63%
EPS growth at 50-75% of WEED.TO's 155.14%. Martin Whitman would suspect a lag in operational efficiency or a higher share count.
94.63%
Diluted EPS growth at 50-75% of WEED.TO's 145.41%. Martin Whitman would question if share issuance or modest net income gains hamper progress.
0.77%
Share count expansion well above WEED.TO's 1.50%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.77%
Diluted share reduction more than 1.5x WEED.TO's 6.88%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-1372.80%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-213.23%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
2699.78%
5Y revenue/share CAGR above 1.5x WEED.TO's 426.42%. David Dodd would look for consistent product or market expansions fueling outperformance.
995.84%
3Y revenue/share CAGR above 1.5x WEED.TO's 173.92%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
-10471.05%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-1899.91%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-745.55%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-322.72%
Negative 10Y net income/share CAGR while WEED.TO is at 271127.90%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-96.58%
Negative 5Y net income/share CAGR while WEED.TO is 2782.22%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-115.70%
Negative 3Y CAGR while WEED.TO is 354.77%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
5649.27%
10Y equity/share CAGR above 1.5x WEED.TO's 1836.75%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
2476.44%
5Y equity/share CAGR above 1.5x WEED.TO's 744.14%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
188.63%
3Y equity/share CAGR above 1.5x WEED.TO's 89.71%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
53.57%
AR growth well above WEED.TO's 15.17%. Michael Burry fears inflated revenue or higher default risk in the near future.
37.86%
Inventory growth well above WEED.TO's 11.87%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
5.69%
Asset growth above 1.5x WEED.TO's 2.10%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
5.89%
Under 50% of WEED.TO's 16.44%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
8.09%
Debt growth far above WEED.TO's 6.81%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-72.57%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
8.97%
We expand SG&A while WEED.TO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.